Oral factor Xa inhibitors have rapid onset of action and obviates the need for heparin in the acute management of venous thrombosis.
Associated with shorter half-life and therefore can improve safety profile, but can provide less protection if doses are missed.
Metabolized by cytochrome P-450 3A4 (CYP3A4) and are substrates for P-glycoprotein.
Agents that inhibit CYP3A4 and P-glycoprotein pathways are contraindicated.
Rivaroxaban can be administered at a fixed dose because gender and body weight do not have clinically relevant influence on pharmacodynamics and pharmacokinetics.
Rivaroxaban has few drug interactions, and administration with food only minimally changes peak plasma concentrations.
Rivaroxaban Is metabolized in the liver, but more than 30% of the drug is excreted in the feces unchanged.
Rivaroxaban metabolism is in part mediated by P glycoprotein. and drugs that are strong inhibitors of CYP3A4 can interfere with this drug metabolism and increase its plasma concentration.